Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    AMP945

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Amplia Investor Presentation Reveal Additional Confirmed Response
    Amplia Investor Presentation Reveal Additional Confirmed Response

    12 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/12/3204647/0/en/Additional-Confirmed-Response-Reported-as-Part-of-Amplia-Investor-Presentation.html

    GLOBENEWSWIRE
    12 Dec 2025
    Share Share
    Key Narmafotinib Patent Granted In U.S.
    Key Narmafotinib Patent Granted In U.S.

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3198906/0/en/Key-Narmafotinib-Patent-Granted-in-the-U-S.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share
    Adagene Starts Investigator-Led Ph 2 Trial of Muzastotug
    Adagene Starts Investigator-Led Ph 2 Trial of Muzastotug

    27 Feb 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/02/27/3033784/0/en/Adagene-Announces-Investigator-Initiated-Phase-2-Trial-for-Neoadjuvant-Muzastotug-ADG126-in-Colorectal-Cancer.html

    GLOBENEWSWIRE
    27 Feb 2025
    Share Share
    Adagene Updates Muzastotug, Keytruda Data In Colorectal Cancer
    Adagene Updates Muzastotug, Keytruda Data In Colorectal Cancer

    27 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/27/3015470/0/en/Adagene-Announces-Updated-Data-from-Phase-1b-2-Study-of-Muzastotug-in-Combination-with-KEYTRUDA-pembrolizumab-in-Colorectal-Cancer-at-ASCO-Gastrointestinal-Cancers-Symposium.html

    GLOBENEWSWIRE
    27 Jan 2025
    Share Share
    Adagene To Present Muzastotug Data With Keytruda At GI Symposium
    Adagene To Present Muzastotug Data With Keytruda At GI Symposium

    21 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/21/3013103/0/en/Adagene-to-Announce-Updated-Data-from-Phase-1b-2-Study-of-Muzastotug-in-Combination-with-KEYTRUDA-pembrolizumab-in-Colorectal-Cancer-at-ASCO-Gastrointestinal-Cancers-Symposium.html

    GLOBENEWSWIRE
    21 Jan 2025
    Share Share
    Adagene Presents Data on Anti-CTLA-4 SAFEbody® ADG126 at SITC
    Adagene Presents Data on Anti-CTLA-4 SAFEbody® ADG126 at SITC

    07 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/07/2976860/0/en/Adagene-Presents-Two-Posters-with-New-Insights-on-Increased-Therapeutic-Index-for-Masked-Anti-CTLA-4-SAFEbody-ADG126-Muzastotug-and-Data-Reinforcing-Clinical-Safety-and-Efficacy-fo.html

    GLOBENEWSWIRE
    07 Nov 2024
    Share Share